In the previous publication, the usage of SGLT2 inhibitors on T2DM patients who already took the dipeptidyl peptidase-4 inhibitor monotherapy can reduce the glycated hemoglobin level of about 0.71% 5. Here, DPP4 is linked to type 2 diabetes mellitus.